Turn Your GLP-1 Patients
Into the Real-World Evidence
Your Pipeline Needs.
30–50% of GLP-1 patients discontinue within six months. Every one of them is a lost outcome, a lost data point, and a lost story. SureMediks closes the gap between visits — extending adherence, capturing real-world evidence, and giving your medical affairs and commercial teams the longitudinal patient journey your clinical trials never could.
standard of care
longitudinal data
See Exactly How SureMediks Extends Your Therapy.
Click any phase below to see the modules, the data captured, and what Realistic Intelligence® does — through whichever lens matters to your team.
Without SureMediks: she silently discontinues by Day 21. She tells her friends the medication "didn't work for her." Her data never enters your post-marketing dataset. She becomes part of the 30–50% statistic that follows your therapy in every market access conversation.
With SureMediks: her tolerance signal routes through Realistic Intelligence®, the coach gets the alert within hours, the dose is paused and a hydration protocol is delivered through the patient app. By Day 25 she's titrating again. She stays on therapy through month 6, month 12, month 18 — generating the kind of longitudinal real-world evidence your medical affairs team can publish, your commercial team can cite, and your HEOR team can present to payers.
This is what "extending therapy beyond the prescription" actually looks like.
More Than a Patient Support
Programme. A Real-World
Evidence Engine.
Most pharma-funded support programmes are call centres with apps bolted on. SureMediks is a clinical-grade platform that extends your therapy, captures the data your pipeline needs, and meets the regulatory bar your medical affairs team requires.
- White-label deployment under your brand or co-branded
- 21 CFR Part 11 and GxP-aligned data capture
- Validated patient-reported outcomes (PROs) at scale
- Realistic Intelligence® — provider-coded protocols, not generic AI
- Continuous longitudinal data — adherence, weight, comorbidities, PROs
- Publication-ready datasets for medical affairs and HEOR
- Privacy-first architecture · HIPAA · patient-consented
Let's Map This Onto Your Therapy.
A 30-minute partnership call to map this six-phase walkthrough onto your therapy, your indication, your medical affairs strategy and your real-world evidence priorities. No pitch deck. A conversation between people who care about extending therapy beyond the prescription.